Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 55
Filter
2.
Sci Rep ; 12(1): 15078, 2022 09 05.
Article in English | MEDLINE | ID: mdl-36064563

ABSTRACT

With the introduction of the latest class of biologic drugs targeting interleukin (IL)-23p19, three new, highly effective drugs can be used for the treatment of chronic plaque psoriasis. However, poorer skin improvement as well as higher rates of serious adverse events have been reported for patients under real-world conditions (outside clinical trials). This accounts especially for patients who have already been treated with biologic drugs. We therefore aimed to determine effectiveness and safety of IL-23p19 inhibitors in real-world patients by analysing data from the Psoriasis Registry Austria (PsoRA) in this observational, retrospective, multicentre cohort study. Data for 197 patients (52.3% biologic-non-naïve), who were treated with anti-IL-23p19 antibodies (127 guselkumab, 55 risankizumab and 15 tildrakizumab) for at least 3 months, were eligible for analysis. In general, biologic-non-naïve patients displayed a less favourable response to anti-IL-23 treatment as compared to biologic-naïve patients. However, after correction for previous biologic exposure, few differences in PASI improvement were detected among biologic-naïve and -non-naïve patients treated with different IL-23p19 inhibitors. This indicates that treatment effectiveness is not related to the class of the previously administered therapy in biologic-non-naïve patients. Therefore, IL-23p19 inhibitors represent a promising treatment alternative for patients who have not responded to previous biologics. However, as with other biologic agents (including IL-17 inhibitors), we did not observe an entirely satisfactory treatment response (i.e. PASI < 3 and/or PASI 75) to anti-IL-23 treatment in one out of four to five patients. Adverse events (mainly non-severe infections) were observed in 23 (11.7%) patients with no major differences regarding the administered IL-23 inhibitor or previous biologic exposure.


Subject(s)
Biological Products , Graft vs Host Disease , Psoriasis , Austria/epidemiology , Biological Products/therapeutic use , Cohort Studies , Graft vs Host Disease/drug therapy , Humans , Interleukin-23 , Psoriasis/drug therapy , Registries , Retrospective Studies , Severity of Illness Index , Treatment Outcome
3.
Br J Dermatol ; 184(6): 1094-1105, 2021 06.
Article in English | MEDLINE | ID: mdl-33289075

ABSTRACT

BACKGROUND: Drug survival rates reflect efficacy and safety and may be influenced by the availability of alternative treatment options. Little is known about time-dependent drug survival in psoriasis and the effect of increasing numbers of biologic treatment options. OBJECTIVES: To determine whether drug survival is influenced by the availability of treatment options and by factors such as gender, psoriatic arthritis or previous biologic treatment. METHODS: This observational, retrospective, multicentre cohort study analysed data from patients registered in the Austrian Psoriasis Registry (PsoRA) who were treated with biologics between 1 January 2015 and 30 November 2019. RESULTS: A total of 1572 patients who received 1848 treatment cycles were included in this analysis. The highest long-term Psoriasis Area and Severity Index improvement was observed after treatment with ixekizumab, followed by ustekinumab and secukinumab, adalimumab and etanercept. Overall, ustekinumab surpassed all other biologics in drug survival up to 48 months. However, when adjusted for biologic naïvety, its superiority vanished and drug survival rates were similar for ixekizumab (91·6%), secukinumab (90·2%) and ustekinumab (92·8%), all of them superior to adalimumab (76·5%) and etanercept (71·9%) at 12 months and beyond. Besides biologic non-naïvety (2·10, P < 0·001), the introduction of a new drug such as secukinumab or ixekizumab (relative hazard ratio 1·6, P = 0·001) and female gender (1·50, P = 0·019) increased the risk of treatment discontinuation overall, whereas psoriatic arthritis did not (1·12, P = 0·21). CONCLUSIONS: The time-dependent availability of drugs should be considered when analysing and comparing drug survival. Previous biologic exposure significantly influences drug survival. Women are more likely to stop treatment.


Subject(s)
Biological Products , Psoriasis , Adalimumab , Austria , Cohort Studies , Etanercept , Female , Humans , Psoriasis/drug therapy , Registries , Retrospective Studies , Survival Rate , Treatment Outcome , Ustekinumab
4.
Br J Dermatol ; 176(6): 1475-1485, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28118487

ABSTRACT

BACKGROUND: (ECT) is an effective local treatment for cutaneous metastasis. Treatment involves the administration of chemotherapeutic drugs followed by delivery of electrical pulses to the tumour. OBJECTIVES: To investigate the effectiveness of ECT in cutaneous metastases of melanoma and to identify factors that affect (beneficially or adversely) the outcome. METHODS: Thirteen cancer centres in the International Network for Sharing Practices on Electrochemotherapy consecutively and prospectively uploaded data to a common database. ECT consisted of intratumoral or intravenous injection of bleomycin, followed by application of electric pulses under local or general anaesthesia. RESULTS: In total, 151 patients with metastatic melanoma were identified from the database, 114 of whom had follow-up data of 60 days or more. Eighty-four of these patients (74%) experienced an overall response (OR = complete response + partial response). Overall, 394 lesions were treated, of which 306 (78%) showed OR, with 229 showing complete response (58%). In multivariate analysis, factors positively associated with overall response were coverage of deep margins, absence of visceral metastases, presence of lymphoedema and treatment of nonirradiated areas. Factors significantly associated with complete response to ECT treatment were coverage of deep margins, previous irradiation of the treated area and tumour size (< 3 cm). One-year overall survival in this cohort of patients was 67% (95% confidence interval 57-77%), while melanoma-specific survival was 74% (95% confidence interval 64-84%). No serious adverse events were reported, and the treatment was in general very well tolerated. CONCLUSIONS: ECT is a highly effective local treatment for melanoma metastases in the skin, with no severe adverse effects noted in this study. In the presence of certain clinical factors, ECT may be considered for local tumour control as an alternative to established local treatments, or as an adjunct to systemic treatments.


Subject(s)
Electrochemotherapy/methods , Melanoma/drug therapy , Skin Neoplasms/drug therapy , Aged , Aged, 80 and over , Anesthesia/methods , Disease Progression , Electrochemotherapy/adverse effects , Electrochemotherapy/instrumentation , Electrodes , Female , Humans , Kaplan-Meier Estimate , Male , Melanoma/mortality , Melanoma/pathology , Neoplasm Metastasis , Pain/etiology , Pain Measurement , Prospective Studies , Skin Neoplasms/mortality , Skin Neoplasms/pathology , Treatment Outcome , Tumor Burden
5.
J Eur Acad Dermatol Venereol ; 29(9): 1742-9, 2015 Sep.
Article in English | MEDLINE | ID: mdl-25665143

ABSTRACT

BACKGROUND: Ample evidence shows that switching from one biological agent to another may prove effective when response to the first one is inadequate. Nevertheless, there are little data so far showing the efficacy and safety of adalimumab in patients with plaque psoriasis who previously received another biologic agent. OBJECTIVE: We evaluated the 1-year effectiveness, safety and quality-of-life outcomes patients with psoriasis who had switched to adalimumab from other biologic therapies. METHODS: Forty-two patients who participated in this Austrian multicenter study were treated with adalimumab over a 1-year period, after switching from efalizumab, infliximab or etanercept. Effectiveness was assessed using standardized tools for measurement of disease severity [Psoriasis Area and Severity Index (PASI) and Nail Psoriasis Severity Index (NAPSI)] and quality of life [Dermatology Life Quality Index (DLQI)]. The study endpoints were evaluated using the all-treated population. RESULTS: The mean percentage of improvement at the end of the study was 74.3% for PASI, 81.6% for DLQI and 83.6% for NAPSI, demonstrating a considerable benefit of treatment with adalimumab. The safety profile observed was consistent with previous clinical trials for adalimumab, and no new safety signals were observed. CONCLUSION: Adalimumab therapy in patients with plaque psoriasis previously treated with other biologic agents demonstrates effectiveness, safety and improvement in quality of life.


Subject(s)
Adalimumab/therapeutic use , Biological Products/therapeutic use , Psoriasis/drug therapy , Anti-Inflammatory Agents/therapeutic use , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized , Cell Migration Inhibition , Dermatologic Agents/therapeutic use , Etanercept/therapeutic use , Follow-Up Studies , Humans , Immunosuppressive Agents/therapeutic use , Infliximab/therapeutic use , Prospective Studies , Psoriasis/diagnosis , Quality of Life , Severity of Illness Index , Treatment Outcome
6.
Peptides ; 32(9): 1840-8, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21871510

ABSTRACT

Tissue inhibitor of metalloproteinases-2 (TIMP-2) inhibits angiogenesis by several mechanisms involving either MMP inhibition or direct endothelial cell binding. The primary aim of this study was to identify the TIMP-2 region involved in binding to the previously identified receptor integrin α3ß1, and to determine whether synthetic peptides derived from this region retained angio-inhibitory and tumor suppressor activity. We demonstrated that the N-terminal domain of TIMP-2 (N-TIMP-2) binds to α3ß1 and inhibits vascular endothelial growth factor-stimulated endothelial cell growth in vitro, suggesting that both the α3ß1-binding domain and the growth suppressor activity of TIMP-2 localize to the N-terminal domain. Using a peptide array approach we identify a 24 amino acid region of TIMP-2 primary sequence, consisting of residues Ile43-Ala66, which shows α3ß1-binding activity. Subsequently we demonstrate that synthetic peptides from this region compete for TIMP-2 binding to α3ß1 and suppress endothelial growth in vitro. We define a minimal peptide sequence (peptide 8-9) that possesses both angio-inhibitory and, using a murine xenograft model of Kaposi's sarcoma, anti-tumorigenic activity in vivo. Thus, both the α3ß1-binding and the angio-inhibitory activities co-localize to a solvent exposed, flexible region in the TIMP-2 primary sequence that is unique in amino acid sequence compared with other members of the TIMP family. Furthermore, comparison of the TIMP-2 and TIMP-1 protein 3-D structures in this region also identified unique structural differences. Our findings demonstrate that the integrin binding, tumor growth suppressor and in vivo angio-inhibitory activities of TIMP-2 are intimately associated within a unique sequence/structural loop (B-C loop).


Subject(s)
Angiogenesis Inhibitors/pharmacology , Antineoplastic Agents/pharmacology , Integrin alpha3beta1/metabolism , Tissue Inhibitor of Metalloproteinase-2/metabolism , Amino Acid Sequence , Animals , Endothelium, Vascular/drug effects , Endothelium, Vascular/metabolism , Humans , Mice , Mice, Nude , Microarray Analysis , Molecular Sequence Data , Neovascularization, Pathologic/metabolism , Peptides/administration & dosage , Peptides/chemical synthesis , Peptides/pharmacology , Protein Binding , Sarcoma, Kaposi/pathology , Tissue Inhibitor of Metalloproteinase-1/chemistry , Tissue Inhibitor of Metalloproteinase-1/metabolism , Tissue Inhibitor of Metalloproteinase-2/chemistry , Vascular Endothelial Growth Factor A/pharmacology
7.
Methods Mol Biol ; 527: 257-67, x, 2009.
Article in English | MEDLINE | ID: mdl-19241019

ABSTRACT

In view of the importance of information transfer mediated throughout the cell by recognition, phosphorylation or dephosphorylation of kinases, their adapters, or substrates, this method was developed. The method provides a potent research tool for rapidly generating and testing these substrates as modeled by synthetic peptide arrays. The peptides or phosphorylated peptides are automatically generated on the inner surfaces of microplate wells, covalently linked to a polylysine polymer so that they are in a sterically favorable conformation, immediately available for in situ testing. Products up to 18 amino acids long have shown excellent mass spectral homogeneity. Thus, determinate peptide libraries can be ready for testing in as little as 2 days after the conception of an experiment. The process can be easily automated using robotic liquid handlers and is extremely rapid, sensitive, and economical. Optionally, the method can be upgraded to a higher throughput level using more powerful workstations with greater capacity, such as the Biomek FX, or any similar robotics capable of transfer-from-file logic to guide synthesis cycles.


Subject(s)
Phosphopeptides/biosynthesis , Protein Array Analysis/instrumentation , Protein Array Analysis/methods , Protein-Tyrosine Kinases/analysis , Protein-Tyrosine Kinases/metabolism , Animals , Antibodies, Immobilized/metabolism , Antibodies, Immobilized/pharmacology , Antibodies, Phospho-Specific/metabolism , Antibodies, Phospho-Specific/pharmacology , Automation/instrumentation , Automation/methods , Humans , Microchemistry/instrumentation , Microchemistry/methods , Phosphopeptides/analysis
8.
J Cell Sci ; 110 ( Pt 2): 249-56, 1997 Jan.
Article in English | MEDLINE | ID: mdl-9044055

ABSTRACT

In order to understand the importance of cell attachment to HIV-1 Tat, we quantified the strength of cell attachment to immobilized Tat in microtiter plate wells by the application of buoyant force. By replacing the attachment medium with dense medium, and subjecting the attached cells in the microtiter plates to centrifugal force in the conventional upright position, weakly binding and strongly binding cells could be discriminated (and separated) by varying the centrifugal speed. The strength of attachment of HT1080 cells to Tat was compared with that of the well-known extracellular matrix (ECM) proteins fibronectin and vitronectin. We observed that all three proteins mediated significant attachment of HT1080 cells both at 4 degrees C and 37 degrees C. However, unlike the ECM proteins, Tat was unable to engage in higher strength binding when the temperature was raised to 37 degrees C. The relatively weak binding of HT1080 cells to Tat (in the order of 3.0 mudynes/picomole of coated Tat) and lack of strengthening of binding to Tat at physiologic temperature suggests that this protein does not mimic adhesion molecule function. We anticipate that the methodology developed and described here will be useful in a wide variety of cell-matrix and cell-cell interaction studies.


Subject(s)
Gene Products, tat/metabolism , HIV-1/metabolism , Dose-Response Relationship, Drug , Fibronectins/metabolism , Humans , Tumor Cells, Cultured , Vitronectin/metabolism , tat Gene Products, Human Immunodeficiency Virus
10.
AIDS Res Hum Retroviruses ; 10(11): 1581-3, 1994 Nov.
Article in English | MEDLINE | ID: mdl-7888214

ABSTRACT

PIP: Nucleotide sequences were obtained for portions of the envelope and gag genes of 4 HIV-1 isolates from Nigeria. The gag gene sequences clustered with previously described gag sequences from Gabon, Zaire, and Taiwan, which form the G clade of HIV-1. This documented for the first time the presence of subgroup G viruses in Nigeria. The env gene sequences were most closely related to env sequences reported from 2 isolates previously classified as gag subgroup G and, with those 2 env sequences, defined the subgroup G env genotype. Virus isolates were obtained by cocultivation of peripheral blood mononuclear cells (PBMCs) from Nigerian AIDS patients (isolates JV1018 and JP88) or healthy prostitutes (G3 and G9) with normal uninfected PBMCs (JV1083, JP88, and G3) or GEM-SS, a T cell line (G9). Clones containing env and gag gene sequences were obtained by polymerase chain reaction amplification, using DNA from these cultures. The region of gag amplified by primers SK37 and SK39 containing BamHI and KpnI sites, respectively, in 5' tails, was cloned into the KpnI-BamHI site of pKSBluescript and sequenced. When the gag sequences from 2 of the Nigerian viruses were subtyped by weighted parsimony, both viruses grouped with others of the gag G subgroup. A similar analysis of env sequences from all 4 Nigerian isolates showed that they were most closely related to 2 env sequences that had been assigned to env subgroup G. The Nigerian env sequences clustered more closely with each other than they did with the other 2 subgroup G viruses. Consensus of the inferred amino acid sequences of the 4 env genes showed that the V3 loop closely resembled the A to F consensus. 8 positions in the Nigerian consensus sequence appeared to be unique. However, whether these are signature residues for Nigerian subgroup G isolates or for subgroup G isolates will require the characterization of more isolates.^ieng


Subject(s)
HIV Infections/virology , HIV-1/classification , HIV-1/genetics , Amino Acid Sequence , Base Sequence , Consensus Sequence , DNA Primers/genetics , DNA, Viral/genetics , Female , Genes, env , Genes, gag , HIV Infections/epidemiology , HIV-1/isolation & purification , Humans , Molecular Sequence Data , Nigeria/epidemiology , Phylogeny , Sequence Homology, Amino Acid
12.
J Virol ; 68(4): 2693-707, 1994 Apr.
Article in English | MEDLINE | ID: mdl-7908063

ABSTRACT

Homologous env sequences from 17 human T-leukemia/lymphotropic virus type I (HTLV-I) strains from throughout the world and from 25 simian T-leukemia/lymphotropic virus type I (STLV-I) strains from 12 simian species in Asia and Africa were analyzed in a phylogenetic context as an approach to resolving the natural history of these related retroviruses. STLV-I exhibited greater overall sequence variation between strains (1 to 18% compared with 0 to 9% for HTLV-I), supporting the simian origin of the modern viruses in all species. Three HTLV-I phylogenetic clusters or clades (cosmopolitan, Zaire, and Melanesia) were resolved with phenetic, parsimony, and likelihood analytical procedures. Seven phylogenetic clusters of STLV-I were resolved with the most primitive (deeply rooted) divergence involving several STLV-I strains from Asian primate species. Combined analysis of HTLV-I and STLV-I revealed that neither STLV-I clusters nor HTLV-I clusters recapitulated host species specificity; rather, multiple clades from the same species were closer to clades from other species than to each other. We interpret these evolutionary associations as support for the occurrence of multiple discrete interspecies transmissions of ancestral viruses between primate species (including human) that led to recognizable phylogenetic clades that persist in modern species. Geographic concordance of divergent host species that harbor closely related viruses reinforces that physical feasibility for hypothesized interspecies virus transmission in the past and in the present.


Subject(s)
Deltaretrovirus Infections/transmission , Genes, env/genetics , Haplorhini/microbiology , Human T-lymphotropic virus 1/classification , Simian T-lymphotropic virus 1/classification , Amino Acid Sequence , Animals , Cercopithecidae , Cloning, Molecular , Deltaretrovirus Infections/blood , Human T-lymphotropic virus 1/genetics , Humans , Molecular Sequence Data , Pan troglodytes , Phylogeny , Polymerase Chain Reaction , Sequence Alignment , Sequence Analysis , Sequence Homology, Amino Acid , Sequence Homology, Nucleic Acid , Simian T-lymphotropic virus 1/genetics , Species Specificity
14.
Leukemia ; 6(11): 1229-31, 1992 Nov.
Article in English | MEDLINE | ID: mdl-1331626

ABSTRACT

Human herpesvirus-6 (HHV-6), a ubiquitous virus that causes exanthem subitum and occasional cases of infectious mononucleosis, hepatitis and other viral syndromes, has also been associated with acute lymphocytic leukemia (ALL) in children. To further investigate this association, we obtained sera from 50 patients with ALL and 50 age-sex matched controls. Antibodies to HHV-6 were determined using ELISA and indirect immunofluorescent antibody (IFA) tests. No significant difference between antibody titers in the cases and controls was observed. Since seroepidemiologic studies have demonstrated higher HHV-6 antibody titers in young children than in adults, this serologic study suggests that the previous association reported for HHV-6 and ALL was a result of the age of the population rather than a relationship between the virus and the disease.


Subject(s)
Antibodies, Viral/analysis , Herpesviridae Infections/complications , Herpesvirus 6, Human/immunology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications , Adolescent , Adult , Child , Child, Preschool , Female , Humans , Infant , Male , Middle Aged
15.
J Virol ; 66(7): 4546-50, 1992 Jul.
Article in English | MEDLINE | ID: mdl-1602560

ABSTRACT

The principal neutralizing epitope of the human immunodeficiency virus type 1 (HIV-1) lies between two invariant cysteines in the third variable region (V3) of the viral envelope (gp120), and its amino acid sequence varies among different HIV-1 isolates. HIV-2 carries an analogous amino acid sequence between two cysteines of the V3 regions, but its functional similarity with the HIV-1 principal neutralizing epitope is uncertain. We studied the degree of genetic variation of the HIV-2 V3 region in fresh blood samples from 12 HIV-2-seropositive individuals from Guinea-Bissau. Polymerase chain reaction was used to amplify viral fragments of 465 bp containing the V3 region from cellular DNA. Nucleotide sequence analysis of the entire envelope fragment from each patient revealed that the degree of variation among field isolates of HIV-2 is comparable to that observed in the analogous region of HIV-1. Most of the HIV-2 isolates studied were highly related, suggesting the existence of a limited number of different viral strains in the cohort studied. Thus, the HIV-2 and HIV-1 V3 regions vary to a similar degree and may also have analogous functions.


Subject(s)
Gene Products, env/genetics , Genetic Variation , HIV-2/genetics , Protein Precursors/genetics , Amino Acid Sequence , Base Sequence , DNA, Viral , HIV Envelope Protein gp120/genetics , HIV Seropositivity/microbiology , HIV-1/genetics , Humans , Molecular Sequence Data , Peptide Fragments/genetics , Polymerase Chain Reaction , Sequence Alignment , Simian Immunodeficiency Virus/genetics , Viral Envelope Proteins , env Gene Products, Human Immunodeficiency Virus
16.
Int J Cancer ; 51(1): 53-7, 1992 Apr 22.
Article in English | MEDLINE | ID: mdl-1314231

ABSTRACT

Serial serum samples from 37 patients with Hodgkin's disease (HD) and 39 healthy controls were studied for antibodies to human herpes virus-6 (HHV-6) using ELISA and indirect immunofluorescent antibody (IFA) tests and to the Epstein-Barr virus (EBV) using a radio-complement fixation assay. Antibodies to HHV-6 in the pre-treatment sera from the HD patients were not significantly different from those of controls, but significant changes in titers related to clinical course were noted among the HD patients. HHV-6 IFA titers increased significantly in the course of follow-up in patients who relapsed and decreased significantly over time in patients who did not. These serologic studies support tissue-based investigations indicating that EBV plays a greater etiologic role in HD than HHV-6, although HHV-6 serology may be of prognostic value or may assist in identifying individuals with immunologic abnormalities. The identification of diverse HHV-6 antibody patterns using different assays may reflect the presence of a number of antibodies with varying implications, similar to those identified for EBV.


Subject(s)
Antibodies, Viral/analysis , Herpesvirus 6, Human/immunology , Hodgkin Disease/immunology , Adolescent , Adult , Aged , Child , Child, Preschool , Enzyme-Linked Immunosorbent Assay , Female , Fluorescent Antibody Technique , Follow-Up Studies , Hodgkin Disease/microbiology , Humans , Male , Middle Aged , Prognosis , Recurrence
17.
Am J Trop Med Hyg ; 42(4): 374-9, 1990 Apr.
Article in English | MEDLINE | ID: mdl-1970459

ABSTRACT

The human T-lymphotropic virus (HTLV) and associated diseases, adult T cell leukemia and spastic paraparesis, appear to be endemic in southwestern Japan and the Caribbean. This cross-sectional population-based study was conducted to describe the seroepidemiology of HTLV in the Republic of Panama. HTLV antibody was measured by first generation and commercial ELISA tests and confirmed by competitive binding ELISA, a radioimmunoassay for anti-p 24, and Western blot. Of 3,231 subjects greater than or equal to 15 years of age, 135 (4.2%) had antibody detected in ELISA screening tests, but because only 20% were confirmed positive, HTLV seroprevalence varied from 0.2-2% throughout the Republic. Infection with HTLV clustered in Guaymi Indians living in Bocas del Toro province (9.9% prevalence rate). With the exception of Guaymi Indians, no major geographic, urban/rural, male/female or racial differences in antibody prevalence were observed; specifically, HTLV infection rates were not elevated in black Panamanians. Clustering of infection in an isolated Amerind population must be further investigated. The small proportion of screen-positive sera which confirmed positive illustrates the importance of strict uniform criteria for seropositivity.


Subject(s)
Deltaretrovirus Antibodies/analysis , Deltaretrovirus Infections/epidemiology , Deltaretrovirus/immunology , Binding, Competitive , Blotting, Western , Enzyme-Linked Immunosorbent Assay , Female , Humans , Male , Panama/epidemiology , Radioimmunoassay
18.
Cancer ; 63(11): 2186-91, 1989 Jun 01.
Article in English | MEDLINE | ID: mdl-2720568

ABSTRACT

Serum samples were obtained in a 2-year period (November 1, 1984-December 31, 1986) from 136 Panamanian patients with hematologic malignancies identified by a population-based registry designed for studies investigating human T-cell lymphotropic virus (HTLV)-I. Only three patients had clinical and serologic findings of HTLV-I-associated adult T-cell leukemia/lymphoma (ATLL). The authors conclude that although classical HTLV-I-associated ATLL occurs in the Panamanian population, it is not as prevalent as in other Caribbean populations.


Subject(s)
HTLV-I Antibodies/analysis , Leukemia-Lymphoma, Adult T-Cell/epidemiology , Lymphoproliferative Disorders/microbiology , Aged , Female , Humans , Leukemia-Lymphoma, Adult T-Cell/pathology , Male , Middle Aged , Myeloproliferative Disorders/microbiology , Panama
19.
AIDS ; 3(4): 235-7, 1989 Apr.
Article in English | MEDLINE | ID: mdl-2500957

ABSTRACT

One hundred and ninety-nine patients with a history of intravenous drug abuse, and enrolled on the St Luke's-Roosevelt Hospital Center Methadone Program, had baseline evaluations performed from September 1984 to April 1987. The study was designed to examine immunologic parameters associated with HIV seropositivity and those predictive of progression to AIDS-related complex (ARC) and AIDS. Sixty-four patients (32%) had antibodies to HIV by enzyme-linked immunosorbent assay (ELISA), with confirmation by Western blot and none of these patients had ARC or AIDS at the time of initial evaluation. The mean values for white blood-cell count, absolute lymphocyte count, proportion and absolute CD4, and CD4/CD8 ratio were decreased significantly in the HIV-seropositive group compared with the HIV-seronegative group. On the other hand, levels of circulating beta 2-microglobulin, SCD8, SIL-2R, and HIV p24 antigen were significantly elevated in the HIV-seropositive group compared with the HIV-seronegative group.


Subject(s)
AIDS-Related Complex/immunology , Acquired Immunodeficiency Syndrome/immunology , HIV Antibodies/analysis , Methadone/therapeutic use , Substance-Related Disorders/immunology , AIDS-Related Complex/complications , Acquired Immunodeficiency Syndrome/complications , Adult , Antigens, Differentiation, T-Lymphocyte/analysis , Blotting, Western , Enzyme-Linked Immunosorbent Assay , Female , HIV Antigens/analysis , HIV Core Protein p24 , Humans , Leukocyte Count , Male , New York City , Receptors, Interleukin-2/analysis , Retroviridae Proteins/analysis , Substance-Related Disorders/complications , Substance-Related Disorders/rehabilitation , beta 2-Microglobulin/analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...